Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and expert in trials in critical conditions. He leads a large research group on biomarkers and biotherapies in critical conditions, named MASCOT granted by the Université de Paris Cité and Inserm.
He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum. He was PI and co-PI of several trials including STRONG-HF published in Lancet in 2022.